Latest Breaking News On - Joint european committee - Page 2 : comparemela.com

The relapse benefit of ocrelizumab in multiple sclerosis is confirmed for the first time in patients 60 and older starting therapy, say researchers in findings they hope will inform choices.

South australiaYi chao foongOcrelizumab ocrevusPavan bhargavaAmericas committee for treatmentJohns hopkins precision medicine centerResearch in multiple sclerosisCentral clinical schoolEuropean committee for treatmentMonash universityDepartment of neuroscienceJoint european committeeMultiple sclerosis americas committeeMultiple sclerosisExpanded disability status scaleMedscape medical